Description; General description; The gene SPRY2 (Sprouty homolog 2) is mapped to human chromosome 13q31.1. SPRY2 localizes in the cytoplasm and co-localizes with microtubules.; Immunogen; Synthetic peptide directed towards the N terminal region of human SPRY2; Application; Anti-SPRY2 antibody produced in rabbit is suitable for western blotting at a concentration of 1.0μg/ml.; Physical form; Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.; Disclaimer; Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.; Biochem/physiol Actions; Sprouty proteins are inhibitors of receptor tyrosine kinase signaling proteins and mediators of organogenesis, branching of lung alveoli and endothelial tubes. They inhibit the activity of Ras/Erk pathway. SPRY2 (Sprouty homolog 2) is bimodal regulator of epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase signaling. SPRY2 is down-regulated in epithelial ovarian cancer. Down-regulation of SPRY2 in high-grade serous ovarian carcinoma promotes EGF-induced E-cadherin levels, thereby resulting in cell invasion.; Sequence; Synthetic peptide located within the following region: MEARAQSGNGSQPLLQTPRDGGRQRGEPDPRDALTQQVHVLSLDQIRAIR